Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,389
datasets available to search
ShareScore release 0.9.0
Dataset results
3,389 results for “asthma”
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
ClinicalTrials.gov study NCT02571777. IPD Sharing: UNDECIDED. Countries: 41. Publications: 5.
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
ClinicalTrials.gov study NCT05421598. IPD Sharing: YES. Countries: 14. Publications: 0.
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
ClinicalTrials.gov study NCT03838731. IPD Sharing: YES. Countries: 1. Publications: 1.
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
ClinicalTrials.gov study NCT02134028. IPD Sharing: YES. Countries: 27. Publications: 16.
Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)
ClinicalTrials.gov study NCT03560466. IPD Sharing: YES. Countries: 18. Publications: 1.
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
ClinicalTrials.gov study NCT02676076. IPD Sharing: YES. Countries: 1. Publications: 6.
Home Air Quality Impact for Adults With Asthma
ClinicalTrials.gov study NCT05224076. IPD Sharing: YES. Countries: 1. Publications: 6.
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
ClinicalTrials.gov study NCT03620747. IPD Sharing: YES. Countries: 10. Publications: 1.
Evaluation of Dupilumab in Children With Uncontrolled Asthma
ClinicalTrials.gov study NCT02948959. IPD Sharing: YES. Countries: 18. Publications: 8.
Data from: Offspring behavioral outcomes following maternal allergic asthma in the IL-4-deficient mouse
Open the record for dataset details and reuse information.
Pediatric Asthma Healthcare Utilization, Viral Testing, and Air Pollution Changes during the COVID-19 Pandemic
<p>Data related to asthma care encounters during the COVID19 pandemic.</p>
Data from: Integrative genomic analysis in African American children with asthma finds 3 novel loci associated with lung function
<p>Bronchodilator drugs are commonly prescribed for treatment and management of obstructive lung function present with diseases such as asthma. Administration of bronchodilator medication can partially or fully restore lung function as measured by pulmonary function tests. The genetics of baseline lung function measures taken prior to bronchodilator medication has been extensively studied, and the genetics of the bronchodilator response itself has received some attention. However, few studies have focused on the genetics of post-bronchodilator lung function. To address this gap, we analyzed lung function phenotypes in 1,103 subjects from the Study of African Americans, Asthma, Genes, and Environment (SAGE), a pediatric asthma case-control cohort, using an integrative genomic analysis approach that combined genotype, locus-specific genetic ancestry, and functional annotation information. We integrated genome-wide association study (GWAS) results with an admixture mapping scan of three pulmonary function tests (FEV1, FVC, and FEV1/FVC) taken before and after albuterol bronchodilator administration on the same subjects, yielding six traits. We identified 18 GWAS loci, and 5 additional loci from admixture mapping, spanning several known and novel lung function candidate genes. Most loci identified via admixture mapping exhibited wide variation in minor allele frequency across genotyped global populations. Functional fine-mapping revealed an enrichment of epigenetic annotations from peripheral blood mononuclear cells, fetal lung tissue, and lung fibroblasts. Our results point to three novel potential genetic drivers of pre- and post-bronchodilator lung function: ADAMTS1, RAD54B, and EGLN3. </p>
Investigating the causal association between immune cell phenotypes and allergic diseases and non-allergic asthma using conventional Two-sample and Bayesian weighted Mendelian randomization
<p>Investigating the causal association between immune cell phenotypes and allergic diseases and non-allergic asthma using conventional Two-sample and Bayesian weighted Mendelian randomization</p>
RaPCO asthma database
<p>The data set of the Rajarata Pregnancy Cohort pertaining to the asthmatic pregnant women without comorbid cardiac conditions.</p>
Warm-Cold Season ORs for ED Asthma, IP Asthma, IP MI, and IH HF
<p>Four graphs display warm-cold season odds ratios (ORs) for emergency department asthma, inpatient asthma, IP myocardial infarction, and IP heart failure in the Baltimore study area 99 12 km<sup>2</sup> Community Multiscale Air Quality grids, and in grids with and without on-the-ground ambient fine PM air monitors.</p>
Development and validation of an asthma self-knowledge questionnaire
<p>These semi-anonymised data involve parameters (sociodemographic, clinical, validation steps) from a cohort of asthmatic and non asthmatic volunteers who collaborated in the study of development and validation of a new questionnaire on knowledge about asthma for lay people.</p>
Lung microbiota analyses in asthma mouse model
<p class="MsoNormal"><span class="Titre2Car"><span>Background:</span></span><span> Asthma is a frequent chronic inflammatory bronchial disease affecting more than 300 million </span><span>patients worldwide, 70% of whom secondary to</span><span> allergy. The diversity of asthmatic endotypes contributes to </span><span>their</span><span> complexity. Many factors, </span><span>such </span><span>as </span><span>the </span><span>environment, allergen sensitization pathways associate with microbiota, influence asthma natural course and explain its phenotypic heterogeneity. Here</span><span>,</span><span> we compared </span><span>a </span><span>mouse model of house dust mite (HDM)-induced allergic asthma sensitized via various routes for </span><span>the </span><span>clinical features of asthma, immune responses, the lung barrier and dysbiosis.</span></p> <p class="MsoNormal"><span class="Titre2Car"><span>Method:</span></span><span> Mice were sensitized HDM by</span> <span>oral, nasal or percutaneous routes. Lung function, barrier integrity, immune response and microbiota composition were analyzed.</span></p> <p class="MsoNormal"><span>Results: </span><span>Severe </span><span>impairment of respiratory function </span><span>was</span><span> observed </span><span>in</span><span> the mice sensitized by the nasal and cutaneous paths. It was associated with epithelial dysfunction characterized by an increased permeability secondary to junction protein disruption. Conversely, </span><span>such sensitization paths induced</span><span> a </span><span>mixed</span><span> eosinophilic and neutrophilic inflammatory response with high IL-17 airways secretion. </span><span>In contrast, oral </span><span>sensitized mice showed a mild impairment of respiratory function. Epithelial dysfunction was lighter with increased mucus production but conserved epithelial junctions. Lung Th2 and eosinophilic inflammation </span><span>were observed</span><span>. Considering lung microbiota, sensitization provoked a significant loss diversity. </span><span>At</span><span> the genus level, </span><span>Cutibacterium, Acinetobacter, Streptococcus and Lactobacillus</span><span> were found to be modulated according to the sensitization pathway. An increase </span><span>in</span><span> anti-inflammatory microbiota metabolites </span><span>was</span><span> observed in the </span><span>oral group</span><span>. </span></p> <p class="MsoNormal"><span>Conclusion: Our study highlights the strong involvement of the sensitization route in allergic asthma physiopathology and the critical </span><span>phenotypic</span><span> diversity in a mouse model.</span></p>
Multi-Omic Approach Associates Blood Methylome with Bronchodilator Drug Response in Pediatric Asthma: Summary statistics
<p>We conducted an epigenome-wide association study of bronchodilator drug response (BDR) in a discovery and validation design. The discovery phase was focused on 221 African American children with asthma. The association between DNA methylation and BDR was conducted using the limma package correcting for age, sex, ancestry, and tissue heterogeneity. Summary statistics include the output from toptable limma function and CpG annotation (based on Illumina EPIC Manifest file v 1.0 B4) organized in the following columns:</p> <ul> <li>Probe: Probe ID</li> <li>Chr: chromosome</li> <li>Pos: genomic position based on GRCh37/hg19</li> <li>Gene: Gene annotation based on Illumina EPIC Manifest file v 1.0 B4</li> <li>logFC: estimate of the log2-fold-change corresponding to the effect or contrast</li> <li>SE: standard error</li> <li>AveExpr: average log2-expression for the probe over all arrays and channels</li> <li>t: moderated t-statistic</li> <li>P.value: raw p-value</li> <li>FDR: adjusted p-value by false discovery rate</li> <li>B: log-odds that the gene is differentially expressed</li> <li>Problem: Flagged potentially problematic probes</li> </ul>
A feasibility randomized controlled superiority trial of fluticasone-vilanterol once daily use for the treatment of mild asthma in adults
<p><strong><span>Objectives</span></strong></p> <p><span>Current international guidelines recommend using a combination of Long-Acting Beta-Agonists and Inhaled Corticosteroids (LABA+ICS) therapy for symptomatic mild asthma. However, this change has yet to be widely implemented in the Middle East. The objective of this pilot study is to assess the feasibility (recruitment and retention rates) of conducting a future definitive RCT to investigate the effectiveness of fluticasone-vilanterol (LABA+ICS) in the management of mild asthma in adults, compared with usual care. </span></p> <p><strong><span>Design</span></strong></p> <p><span>This 8-month parallel two-arm pilot trial took place in the Kingdom of Bahrain. We randomly assigned 18 patients with mild asthma in a 1:1 ratio to the treatment (n=10) or usual care (n=8) arms. The treatment group received daily LABA+ICS therapy while the usual care group continued </span><span>as required </span><span>SABA or SABA+ICS combination</span><span>. The main outcome measures were descriptors of study feasibility (recruitment and retention rates). We also compared unblinded outcome assessment of asthma control score, quality of life, and the number of asthma exacerbations experienced by patients in both arms.</span></p> <p><strong><span>Results</span></strong></p> <p><span>A total of 18 patients were recruited from a single primary healthcare center and randomized by remote web-based allocation into intervention (n=10) and usual care (n=8) groups. The baseline characteristics of participants did not differ significantly across the two arms at the start of the trial. Because of slow recruitment and limited funding, the study didn't meet our recruitment target but did successfully meet our retention criteria. At 32 weeks, the analysis indicated significant improvement in asthma control scores in the intervention arm (1.31 vs 2.91; 95% CI </span><span>[0.72, 2.44]; </span><span>P-value=0.003), but no significant differences were noted in quality-of-life scores (P-value=</span><span>0.197) compared to the baseline levels</span><span>. There were no significant differences </span><span>in post-intervention asthma control mean score (</span><span>P-value=</span><span>0.361) or QoL mean score (</span><span>P-value=</span><span>0.337) between the two arms after adjustment for pre-intervention scores. </span></p> <p><strong><span>Conclusions</span></strong></p> <p><span>This pilot RCT indicates that a definitive RCT is feasible in a primary healthcare setting in Bahrain. In a definitive trial, we recommend increasing the recruitment rate by relaxing eligibility criteria, extending the timeline, and increasing the number of sites for recruitment. Additionally, outcomes of this pilot trial suggest that LABA+ICS is a feasible, acceptable, safe, and effective intervention for the management of mild asthma in a Middle Eastern context.</span></p>
Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov study NCT00595114. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.